---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-256290"
form_type: "8-K"
ticker: "SVRA"
cik: "0001160308"
company_name: "Savara Inc"
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:34:59.838744+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Savara secures $75M royalty funding from RTW for MOLBREEVI; also discloses securities class action

## Summary
- RTW commits $75M upon FDA approval of MOLBREEVI for autoimmune PAP; funds to support U.S. launch and repay debt.
- Royalty rates tiered from 7.0% to 1.0% of U.S. net sales; 7.0% tier rises to 9.5% if prior-year sales fall short.
- Royalty capped at $187.5M; company expects effective rate in low-single digits over life of agreement.
- Securities class action filed Sept 8, 2025 alleging misstatements about MOLBREEVI regulatory filings; company intends to defend.

## SEC filing metadata
- accession: 0001193125-25-256290
- form_type: 8-K
- ticker: SVRA
- cik: 0001160308
- company_name: Savara Inc
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1160308/000119312525256290/0001193125-25-256290-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1160308/000119312525256290/d55049d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-256290
- JSON: https://secwatch.observer/filing/0001193125-25-256290.json
- Plain text: https://secwatch.observer/filing/0001193125-25-256290.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.